PT - JOURNAL ARTICLE AU - Aliee, Maryam AU - Rock, Kat S. AU - Keeling, Matt J. TI - Estimating the distribution of time to extinction of infectious diseases in mean-field approaches AID - 10.1101/2020.07.10.20150359 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.10.20150359 4099 - http://medrxiv.org/content/early/2020/11/12/2020.07.10.20150359.short 4100 - http://medrxiv.org/content/early/2020/11/12/2020.07.10.20150359.full AB - A key challenge for many infectious diseases is to predict the time to extinction under specific interventions. In general this question requires the use of stochastic models which recognise the inherent individual-based, chance-driven nature of the dynamics; yet stochastic models are inherently computationally expensive, especially when parameter uncertainty also needs to be incorporated. Deterministic models are often used for prediction as they are more tractable, however their inability to precisely reach zero infections makes forecasting extinction times problematic. Here, we study the extinction problem in deterministic models with the help of an effective “birth-death” description of infection and recovery processes. We present a practical method to estimate the distribution, and therefore robust means and prediction intervals, of extinction times by calculating their different moments within the birth-death framework. We show these predictions agree very well with the results of stochastic models by analysing the simplified SIS dynamics as well as studying an example of more complex and realistic dynamics accounting for the infection and control of African sleeping sickness (Trypanosoma brucei gambiense).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Bill and Melinda Gates Foundation (www.gatesfoundation.org) through the NTD Modelling Consortium [OPP1184344] (M.A., K.S.R. and M.J.K.) and the Human African Trypanosomiasis Modelling and Economic Predictions for Policy (HAT MEPP) project [OPP1177824] (K.S.R. and M.K.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We only use some data that are already preprinted in previous manuscripts and these works are clearly cited.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the necessary data and details of methods are included in the supplementary information.